Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors

INTRODUCTION: The clinical successes seen with anti–programmed cell death protein 1/programmed death-ligand 1 (anti–PD-[L]1) agents have galvanized the field of immuno-oncology. We evaluated the landscape and trends in immunotherapy trials involving the PD-(L)1 axis in intrathoracic tumors. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kareff, Samuel A., Samtani, Suraj, Burotto, Mauricio, Prasad, Vinay, Kim, Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474294/
https://www.ncbi.nlm.nih.gov/pubmed/34590006
http://dx.doi.org/10.1016/j.jtocrr.2021.100149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474294/
https://www.ncbi.nlm.nih.gov/pubmed/34590006
http://dx.doi.org/10.1016/j.jtocrr.2021.100149

Ejemplares similares